Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) Receives $18.38 Average Target Price from Brokerages

Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) has earned a consensus recommendation of “Moderate Buy” from the six ratings firms that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, three have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $18.3750.

SENS has been the topic of several analyst reports. TD Cowen restated a “buy” rating on shares of Senseonics Holdings, Inc. Common Stock in a report on Thursday, January 8th. Weiss Ratings initiated coverage on Senseonics Holdings, Inc. Common Stock in a report on Tuesday, February 17th. They set a “sell (d-)” rating on the stock. Finally, Stifel Nicolaus set a $9.00 price objective on Senseonics Holdings, Inc. Common Stock in a report on Tuesday, March 3rd.

Senseonics Holdings, Inc. Common Stock Stock Up 7.2%

SENS stock opened at $5.36 on Monday. The company has a quick ratio of 4.55, a current ratio of 4.83 and a debt-to-equity ratio of 0.58. Senseonics Holdings, Inc. Common Stock has a 52-week low of $4.79 and a 52-week high of $14.96. The business’s 50 day simple moving average is $6.70. The stock has a market cap of $223.99 million, a P/E ratio of -3.17 and a beta of 1.05.

Insider Activity at Senseonics Holdings, Inc. Common Stock

In other news, CEO Timothy T. Goodnow bought 17,225 shares of the firm’s stock in a transaction dated Friday, March 13th. The stock was bought at an average price of $5.79 per share, for a total transaction of $99,732.75. Following the transaction, the chief executive officer owned 651,243 shares in the company, valued at $3,770,696.97. The trade was a 2.72% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Douglas A. Roeder bought 17,500 shares of the firm’s stock in a transaction dated Friday, March 13th. The stock was purchased at an average price of $5.73 per share, with a total value of $100,275.00. Following the transaction, the director owned 119,731 shares in the company, valued at approximately $686,058.63. This represents a 17.12% increase in their position. The disclosure for this purchase is available in the SEC filing. 4.70% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Ausdal Financial Partners Inc. grew its position in shares of Senseonics Holdings, Inc. Common Stock by 50.0% in the 3rd quarter. Ausdal Financial Partners Inc. now owns 105,000 shares of the company’s stock worth $46,000 after acquiring an additional 35,000 shares in the last quarter. Townsend Asset Management Corp NC ADV acquired a new position in shares of Senseonics Holdings, Inc. Common Stock in the 4th quarter worth approximately $60,000. GSK plc acquired a new position in shares of Senseonics Holdings, Inc. Common Stock in the 4th quarter worth approximately $60,000. Kestra Advisory Services LLC acquired a new position in shares of Senseonics Holdings, Inc. Common Stock in the 1st quarter worth approximately $68,000. Finally, Sanctuary Advisors LLC acquired a new position in shares of Senseonics Holdings, Inc. Common Stock in the 4th quarter worth approximately $71,000. Institutional investors and hedge funds own 12.36% of the company’s stock.

Senseonics Holdings, Inc. Common Stock Company Profile

Senseonics Holdings, Inc develops and commercializes long-term implantable continuous glucose monitoring (CGM) systems for people with diabetes. The company’s primary product family is the Eversense system, which combines a small subcutaneously implanted sensor, a removable external transmitter, and companion smartphone applications to provide continuous glucose readings and alerts. Senseonics positions its technology as an alternative to wearable patch-style CGMs by offering multi-month sensor longevity and on-body vibration alerts delivered through the transmitter.

Senseonics supports clinical and commercial activities that include research and development, regulatory engagement, manufacturing and distribution, and training for healthcare providers who perform sensor insertion and removal.